Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 12841872 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| we tried to identify prostate-specific membrane antigen (psma)-derived peptides capable of eliciting both cellular and humoral immune responses in peripheral blood mononuclear cells (pbmcs) and plasma of hla-a24(+) prostate cancer patients, respectively. | |||||||
| 12841872 | HLA-A*24 | prostate cancer | NA | NA | NA | only_studied | |
| for cellular response, peptide-specific and prostate cancer-reactive responses of in vitro-stimulated pbmcs were examined with regard to interferon (ifn)-gamma production and cytotoxicity against both a parental hla-a24(-) prostate cancer cell line (pc-93) and an hla-a24-expressing transfectant cell line (pc93-a24). | |||||||
| 12841872 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| the psma 624-632 peptide-stimulated pbmcs from either healthy donors or prostate cancer patients produced a significant level of ifn-gamma in response to prostate cancer cells in an hla-a24-restricted manner, and also showed a higher level of cytotoxicity against pc93-a24 than against pc93. | |||||||
| 12841872 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| these results demonstrate that the psma 624-632 peptide could be an appropriate molecule for use in specific immunotherapy of hla-a24(+) patients with prostate cancer. | |||||||
| 12858355 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| identification of an hla-a*0201-restricted t-cell epitope derived from the prostate cancer-associated protein trp-p8. | |||||||
| 12949939 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in hla-a24+ prostate cancer patients. | |||||||
| 12949939 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| we tried to identify prostate-specific antigen (psa)-derived epitopes immunogenic in hla-a24+ prostate cancer patients. | |||||||
| 12949939 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| peripheral blood mononuclear cells (pbmcs) were in vitro stimulated with each of four different psa peptides carrying the hla-a24 binding motif, and their hla-a24-restricted anti-tumor responses were examined using a parental hla-a24-negative prostate cancer cell line (pc93) and its hla-a24-expressing transfectant line (pc93-a24). | |||||||
| 12949939 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| the psa(152-160) and psa(248-257) peptides could be appropriate target molecules in use for specific immunotherapy of hla-a24+ prostate cancer patients. | |||||||
| 14720331 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| phase i trial of patient-oriented vaccination in hla-a2-positive patients with metastatic hormone-refractory prostate cancer. | |||||||
Copyright 2024